Guru Fundamental Report for TMO

Validea's assessment of Thermo Fisher Scientific (TMO) under John Neff's "Low PE Investor" model resulted in a 62% rating, falling short of the 80% threshold for investor interest. While TMO, a large-cap medical equipment firm, demonstrated strong fundamentals including persistent EPS and sales growth, and robust free cash flow, its P/E ratio and total return/PE metrics failed, indicating a valuation that does not align with the model's discount-oriented criteria.

Analysis

Thermo Fisher Scientific (TMO), a large-cap firm in the medical equipment sector, received a 62% rating from Validea's 'Low PE Investor' model, which is based on the strategy of John Neff. This score falls below the 80% threshold considered necessary to indicate notable interest from the model. The analysis reveals a clear divergence between the company's robust underlying fundamentals and its current market valuation. TMO successfully passed criteria for EPS Growth, Future EPS Growth, Sales Growth, Free Cash Flow, and EPS Persistence, signaling a healthy and consistently growing business. However, the stock failed on key valuation metrics, specifically its P/E Ratio and Total Return/PE ratio. This failure indicates that while TMO exhibits strong operational performance, its current market price does not offer the discount relative to earnings growth and yield that is central to the Neff value-investing methodology.

Key Decisions for Investors

• Value-focused investors should note that TMO fails to meet the core criteria of the discount-oriented John Neff model, suggesting it is currently too expensive for this style of investing and a price pullback may be required for consideration.
• Investors with a growth-oriented mandate may find confirmation of strong business fundamentals in the passing scores on EPS, sales growth, and free cash flow, but must weigh this against a valuation that value screens identify as rich.
• Given the mixed assessment of strong fundamentals against a high valuation, investors should monitor for a potential improvement in the relationship between TMO's price and earnings, as this would be necessary to trigger a buy signal from value-based models.